Drug Trial Radar · NCT07192614
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Mar 29, 2029
Study completion Mar 29, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).
Conditions
- Prostate Cancer
Interventions
AZD6621Drug
A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
- Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first study dose to 21 to 28 days post first dose
- Preliminary anti-tumour activity of AZD6621 (PSA Response Rate) (Part B only)Time frame: Up to 3 years
Locations
26 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Orlando, Florida · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
Commack, New York · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Brussels, Belgium · Not yet recruiting
Research Site
Ghent, Belgium · Not yet recruiting
Research Site
Québec, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Chengdu, China · Suspended
Research Site
Guangzhou, China · Suspended
Research Site
Nanjing, China · Not yet recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Hirakata-shi, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Amsterdam, Netherlands · Not yet recruiting
Research Site
Maastricht, Netherlands · Not yet recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
L'Hospitalet de Llobregat, Spain · Not yet recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Cambridge, United Kingdom · Recruiting
Research Site
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.